当前位置：
X-MOL 学术
›
Cent. Eur. J. Immunol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Immune response to hepatitis B vaccination in pediatric patients with inflammatory bowel disease
Central European Journal of Immunology ( IF 1.3 ) Pub Date : 2020-07-27 , DOI: 10.5114/ceji.2020.97902 Marta Baranowska-Nowak 1 , Barbara IwaŃczak 2 , Mariusz Szczepanik 3 , Marcin Banasiuk 4 , Łukasz DembiŃski 4 , Katarzyna Karolewska-Bochenek 4 , Marcin Dziekiewicz 4 , Andrzej Radzikowski 4 , Aleksandra Banaszkiewicz 4
Central European Journal of Immunology ( IF 1.3 ) Pub Date : 2020-07-27 , DOI: 10.5114/ceji.2020.97902 Marta Baranowska-Nowak 1 , Barbara IwaŃczak 2 , Mariusz Szczepanik 3 , Marcin Banasiuk 4 , Łukasz DembiŃski 4 , Katarzyna Karolewska-Bochenek 4 , Marcin Dziekiewicz 4 , Andrzej Radzikowski 4 , Aleksandra Banaszkiewicz 4
Affiliation
Aim of the study
To evaluate the immune response rate in children with inflammatory bowel disease (IBD) who received the full hepatitis B vaccination course in infancy. We also evaluated rates of response to booster doses.
Material and methods
Participants were 1- to 18-year-old children with IBD, who received 3 doses of the hepatitis B vaccine in infancy. The study subjects were on no immunosuppressive therapy, on immunomodulators, on biological therapy, or received combo therapy. Anti-hepatitis B surface antibody (anti-HBs) level ⥠10 mIU/ml was considered to be seroprotective. Patients with anti-HBs level < 10 mIU/ml received 1 or 3 doses of hepatitis B vaccine, and their post-vaccination anti-HBs levels were evaluated.
Results
In total, we included 157 subjects, with a median age of 14.5 years. Anti-HBs levels ⥠10 mIU/ml were found in 84/157 (53.5%) patients and were not associated with age (p = 0.3), sex (p = 0.7), or IBD type (p = 0.9). There was no significant difference in the rate of seroconversion between IBD patients treated with no immunosuppressive drugs, immunomodulators, biologicals, and combo therapy (30.4% vs. 39.3% vs. 2.7% vs. 7.1%, respectively, p = 0.3). After the first and third dose of booster vaccine, anti-HBs levels ⥠10 mIU/ml were as follows: 92% and 100%, respectively.
Conclusions
The immune response in children with IBD, who received the full series of hepatitis B vaccinations in infancy was inadequate and did not depend on the type of therapy. The booster dose(s) of vaccine could help to protect this group of patients from hepatitis B virus.
中文翻译：
儿童炎症性肠病患者对乙型肝炎疫苗接种的免疫反应
研究目的
评估在婴儿期接受完整乙肝疫苗接种课程的炎症性肠病 (IBD) 儿童的免疫应答率。我们还评估了对加强剂量的反应率。
材料和方法
参与者是 1 至 18 岁的 IBD 儿童，他们在婴儿期接种了 3 剂乙肝疫苗。研究对象未接受免疫抑制治疗、免疫调节剂、生物治疗或联合治疗。抗乙型肝炎表面抗体 (anti-HBs) 水平≥ 10 mIU/ml 被认为具有血清保护作用。抗 HBs 水平 < 10 mIU/ml 的患者接受 1 剂或 3 剂乙肝疫苗，并评估其接种后的抗 HBs 水平。
结果
我们总共纳入了 157 名受试者，中位年龄为 14.5 岁。在 84/157 (53.5%) 患者中发现抗 HBs 水平≥ 10 mIU/ml，并且与年龄 (p = 0.3)、性别 (p = 0.7) 或 IBD 类型 (p = 0.9) 无关。未接受免疫抑制药物、免疫调节剂、生物制剂和联合疗法治疗的 IBD 患者的血清转化率没有显着差异（分别为 30.4% vs. 39.3% vs. 2.7% vs. 7.1%，p = 0.3）。加强疫苗第一剂和第三剂后，抗-HBs 水平≥ 10 mIU/ml 分别为：92% 和100%。
结论
在婴儿期接受全套乙肝疫苗接种的 IBD 儿童的免疫反应不足，并且不依赖于治疗类型。加强剂量的疫苗可以帮助保护这组患者免受乙型肝炎病毒的侵害。
更新日期：2020-08-20
To evaluate the immune response rate in children with inflammatory bowel disease (IBD) who received the full hepatitis B vaccination course in infancy. We also evaluated rates of response to booster doses.
Material and methods
Participants were 1- to 18-year-old children with IBD, who received 3 doses of the hepatitis B vaccine in infancy. The study subjects were on no immunosuppressive therapy, on immunomodulators, on biological therapy, or received combo therapy. Anti-hepatitis B surface antibody (anti-HBs) level ⥠10 mIU/ml was considered to be seroprotective. Patients with anti-HBs level < 10 mIU/ml received 1 or 3 doses of hepatitis B vaccine, and their post-vaccination anti-HBs levels were evaluated.
Results
In total, we included 157 subjects, with a median age of 14.5 years. Anti-HBs levels ⥠10 mIU/ml were found in 84/157 (53.5%) patients and were not associated with age (p = 0.3), sex (p = 0.7), or IBD type (p = 0.9). There was no significant difference in the rate of seroconversion between IBD patients treated with no immunosuppressive drugs, immunomodulators, biologicals, and combo therapy (30.4% vs. 39.3% vs. 2.7% vs. 7.1%, respectively, p = 0.3). After the first and third dose of booster vaccine, anti-HBs levels ⥠10 mIU/ml were as follows: 92% and 100%, respectively.
Conclusions
The immune response in children with IBD, who received the full series of hepatitis B vaccinations in infancy was inadequate and did not depend on the type of therapy. The booster dose(s) of vaccine could help to protect this group of patients from hepatitis B virus.
中文翻译：
儿童炎症性肠病患者对乙型肝炎疫苗接种的免疫反应
研究目的
评估在婴儿期接受完整乙肝疫苗接种课程的炎症性肠病 (IBD) 儿童的免疫应答率。我们还评估了对加强剂量的反应率。
材料和方法
参与者是 1 至 18 岁的 IBD 儿童，他们在婴儿期接种了 3 剂乙肝疫苗。研究对象未接受免疫抑制治疗、免疫调节剂、生物治疗或联合治疗。抗乙型肝炎表面抗体 (anti-HBs) 水平≥ 10 mIU/ml 被认为具有血清保护作用。抗 HBs 水平 < 10 mIU/ml 的患者接受 1 剂或 3 剂乙肝疫苗，并评估其接种后的抗 HBs 水平。
结果
我们总共纳入了 157 名受试者，中位年龄为 14.5 岁。在 84/157 (53.5%) 患者中发现抗 HBs 水平≥ 10 mIU/ml，并且与年龄 (p = 0.3)、性别 (p = 0.7) 或 IBD 类型 (p = 0.9) 无关。未接受免疫抑制药物、免疫调节剂、生物制剂和联合疗法治疗的 IBD 患者的血清转化率没有显着差异（分别为 30.4% vs. 39.3% vs. 2.7% vs. 7.1%，p = 0.3）。加强疫苗第一剂和第三剂后，抗-HBs 水平≥ 10 mIU/ml 分别为：92% 和100%。
结论
在婴儿期接受全套乙肝疫苗接种的 IBD 儿童的免疫反应不足，并且不依赖于治疗类型。加强剂量的疫苗可以帮助保护这组患者免受乙型肝炎病毒的侵害。
京公网安备 11010802027423号